120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
中药制剂在呼吸系统炎症性疾病中的研究进展
Authors Liu X, Liu B, Wang S, Tian Y, Liu Y, Cui X, Zhang S
Received 10 June 2025
Accepted for publication 8 January 2026
Published 29 January 2026 Volume 2026:19 545874
DOI https://doi.org/10.2147/JIR.S545874
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Cynthia Koziol-White
Xiuli Liu,1 Bo Liu,1 Shengsheng Wang,2 Yang Tian,1 Ying Liu,1 Xiaoli Cui,1 Shuisheng Zhang3
1Department of Rehabilitation, Jilin Academy of Chinese Medicine Sciences, Changchun, 130022, People’s Republic of China; 2Clinical Drug Trial Institution, Jilin Academy of Chinese Medicine Sciences, Changchun, 130022, People’s Republic of China; 3Department of Geriatrics, Jilin Academy of Chinese Medicine Sciences, Changchun, 130022, People’s Republic of China
Correspondence: Shuisheng Zhang, Department of Geriatrics, Jilin Academy of Chinese Medicine Sciences, No. 6426, Ziyou Road, Nanguan District, Changchun, 130022, Jilin Province, People’s Republic of China, Email shuishengzhang777@163.com
Abstract: The global burden of respiratory inflammatory diseases, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD), continues to rise, highlighting the urgent need for safer and more effective therapeutic strategies. Conventional treatments provide symptomatic relief but remain limited by adverse effects, tolerance, and incomplete resolution of inflammation. In recent years, traditional Chinese medicine (TCM) formulations have gained growing attention as promising complementary or alternative approaches due to their holistic and multi-targeted pharmacological actions. This review summarizes current preclinical and clinical evidence on the application of classical TCM preparations—including Xuebijing, Qingkailing, Xiyanping, Tanreqing, Chuankezhi, Shuanghuanglian, and Yejuhua injections—in the management of respiratory inflammatory diseases. These herbal treatments exhibit significant anti-inflammatory, antioxidative, and immunomodulatory effects through modulation of key signaling pathways such as NF-κB, MAPK, and TLRs. Importantly, clinical studies suggest that these TCM preparations can alleviate respiratory symptoms, reduce disease exacerbations, and enhance patient quality of life, highlighting their potential clinical significance and translational value in managing respiratory inflammatory diseases.
Keywords: traditional Chinese medicine, preparations, respiratory inflammatory disease
1Department of Rehabilitation, Jilin Academy of Chinese Medicine Sciences, Changchun, 130022, People’s Republic of China; 2Clinical Drug Trial Institution, Jilin Academy of Chinese Medicine Sciences, Changchun, 130022, People’s Republic of China; 3Department of Geriatrics, Jilin Academy of Chinese Medicine Sciences, Changchun, 130022, People’s Republic of China
Correspondence: Shuisheng Zhang, Department of Geriatrics, Jilin Academy of Chinese Medicine Sciences, No. 6426, Ziyou Road, Nanguan District, Changchun, 130022, Jilin Province, People’s Republic of China, Email shuishengzhang777@163.com
Abstract: The global burden of respiratory inflammatory diseases, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD), continues to rise, highlighting the urgent need for safer and more effective therapeutic strategies. Conventional treatments provide symptomatic relief but remain limited by adverse effects, tolerance, and incomplete resolution of inflammation. In recent years, traditional Chinese medicine (TCM) formulations have gained growing attention as promising complementary or alternative approaches due to their holistic and multi-targeted pharmacological actions. This review summarizes current preclinical and clinical evidence on the application of classical TCM preparations—including Xuebijing, Qingkailing, Xiyanping, Tanreqing, Chuankezhi, Shuanghuanglian, and Yejuhua injections—in the management of respiratory inflammatory diseases. These herbal treatments exhibit significant anti-inflammatory, antioxidative, and immunomodulatory effects through modulation of key signaling pathways such as NF-κB, MAPK, and TLRs. Importantly, clinical studies suggest that these TCM preparations can alleviate respiratory symptoms, reduce disease exacerbations, and enhance patient quality of life, highlighting their potential clinical significance and translational value in managing respiratory inflammatory diseases.
Keywords: traditional Chinese medicine, preparations, respiratory inflammatory disease